Differential expression of Dickkopf-1 among non-small cell lung cancer cells

Xiang,Xiao  Jun; Liu,Ya  Wen; Chen,Dian  Dian; Yu,Shuang

doi:10.3892/mmr.2015.3654

Differential expression of Dickkopf-1 among non-small cell lung cancer cells

Authors:
- Xiao Jun Xiang
- Ya Wen Liu
- Dian Dian Chen
- Shuang Yu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Oncology, Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. China
Published online on: April 21, 2015 https://doi.org/10.3892/mmr.2015.3654
Pages: 1935-1940

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dickkopf-1 (DKK1) is a negative regulator of the Wnt/β-catenin signaling pathway, which is expressed in various human cancers. It was hypothesized that DKK1 was oncogenic and involved in invasive growth in non‑small cell lung cancer (NSCLC) cells. The present study aimed to investigate whether DKK1 gene expression levels differ among various NSCLC cells. The DKK1 expression pattern was analyzed in various human NSCLC cell lines and tissues. The DKK1 protein and gene expression levels were quantified using immunoblotting, polymerase chain reaction analysis and immunohistochemistry. The majority of the lung cancer cell lines analyzed revealed increased expression levels of DKK1. Furthermore, DKK1 expression was highly transactivated in the majority of these cancer cell lines. Clinical samples were obtained from 98 NSCLC patients for immunohistochemical analysis. Of the 98 samples analyzed, 62 (63.3%) demonstrated positive staining for DKK1, whereas the remaining 36 (37%) exhibited negative staining. However, no immunohistopathological staining was detected in normal tissues. The relative effects of DKK1 were assessed in a high‑expression cell line (LTEP‑a‑2) and a low‑expression cell line (95D). The differential expression of genes involved in cell cycle, apoptosis, signaling pathway, invasion and metastasis were evaluated, relative to DKK1 levels. In conclusion, the results of the present study indicated that DKK1 functioned as a key regulator in the progression of NSCLC. The results confirmed the differential expression of DKK1 in NSCLC cells, which may present a potential therapeutic target for cancer prevention.

View Figures

View References

1	Niida A, Hiroko T, Kasai M, et al: DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene. 23:8520–8526. 2004. View Article : Google Scholar : PubMed/NCBI
2	Gavriatopoulou M, Dimopoulos MA, Christoulas D, et al: Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets. 13:839–848. 2009. View Article : Google Scholar : PubMed/NCBI
3	Forget MA, Turcotte S, Beauseigle D, et al: The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer. 96:646–653. 2007. View Article : Google Scholar : PubMed/NCBI
4	Darlavoix T, Seelentag W, Yan P, Bachmann A and Bosman FT: Altered expression of CD44 and DKK1 in the progression of Barrett’s esophagus to esophageal adenocarcinoma. Virchows Arch. 454:629–637. 2009. View Article : Google Scholar : PubMed/NCBI
5	Makino T, Yamasaki M, Takemasa I, et al: Dickkopf-1 expression as a marker for predicting clinical outcome in esophageal squamous cell carcinoma. Ann Surg Oncol. 16:2058–2064. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wirths O, Waha A, Weggen S, Schirmacher P, Kühne T, et al: Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms’ tumors. Lab Invest. 83:429–434. 2003. View Article : Google Scholar : PubMed/NCBI
7	Marvin MJ, Di Rocco G, Gardiner A, et al: Inhibition of Wnt activity induces heart formation from posterior mesoderm. Genes Dev. 15:316–327. 2001. View Article : Google Scholar : PubMed/NCBI
8	Mountain CF: Revisions in the international system for staging lung cancer. Chest. 111:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
9	Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 109:120–129. 1995. View Article : Google Scholar : PubMed/NCBI
10	Chen WQ, Zheng RS and Zeng HM: Bayesian age-period-cohort prediction of lung cancer incidence in China. Thoracic Cancer. 2:149–155. 2011. View Article : Google Scholar
11	Chen W, Zheng R, Zhang S, Zou X, Zhao P, et al: Lung cancer incidence and mortality in China, 2009. Thoracic Cancer. 4:102–108. 2013. View Article : Google Scholar
12	Zeng H, Zheng R, Zhang S, He J and Chen W: Lung cancer incidence and mortality in China, 2008. Thoracic Cancer. 4:53–58. 2013. View Article : Google Scholar
13	Fukuyama Y, Mitsudomi T, Sugio K, et al: K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer. 75:1125–1130. 1997. View Article : Google Scholar : PubMed/NCBI
14	Osaki T, Mitsudomi T, Oyama T, Nakanishi R and Yasumoto K: Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest. 108:157–162. 1995. View Article : Google Scholar : PubMed/NCBI
15	Oyama T, Osaki T, Mitsudomi T, et al: p53 alteration, proliferating cell nuclear antigen and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med. 1:823–826. 1998.PubMed/NCBI
16	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
17	Tammemägi MC, Katki HA, Hocking WG, et al: Selection criteria for lung-cancer screening. New Engl J Med. 368:728–736. 2013. View Article : Google Scholar : PubMed/NCBI
18	Takahashi N, Fukushima T, Yorita K, Tanaka H, Chijiiwa K, et al: Dickkopf-1 is overexpressed in human pancreatic ductal adenocarcinoma cells and is involved in invasive growth. Int J Cancer. 126:1611–1620. 2010.
19	Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, et al: Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 67:2517–2525. 2007. View Article : Google Scholar : PubMed/NCBI
20	González-Sancho JM, Aguilera O, García JM, et al: The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene. 24:1098–1103. 2005. View Article : Google Scholar
21	Yu B, Yang X, Xu Y, Yao G, Shu H, et al: Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 50:948–957. 2009. View Article : Google Scholar : PubMed/NCBI
22	Sheng SL, Huang G, Yu B and Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 55:1656–1664. 2009. View Article : Google Scholar : PubMed/NCBI
23	Qin X, Zhang H, Zhou X, Wang C, Zhang X, et al: Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl Res. 150:281–294. 2007. View Article : Google Scholar : PubMed/NCBI
24	Yao X, Jiang H, Zhang C, Wang H, Yang L, et al: Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer. Biomarkers. 15:128–134. 2010. View Article : Google Scholar
25	Osada H, Tomida S, Yatabe Y, Tatematsu Y, Takeuchi T, et al: Roles of achaetescute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. Cancer Res. 68:1647–1655. 2008. View Article : Google Scholar : PubMed/NCBI
26	Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, et al: Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis. 29:895–904. 2008. View Article : Google Scholar : PubMed/NCBI